


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 28, 2008 (use as many sheets as necessary)				Complete if Known		
				Application Number	10/573,753	
Sheet		1	of	2	Filing Date	September 30, 2004
					First Named Inventor	Jonathan CEBON
					Art Unit	1644
					Examiner Name	Unknown
					Attorney Docket Number	029860-0145



U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	A1	WO 00/07621	02-17-2000	Smithkline Beecham Biolog		
	A2	WO 01/07917 A1	02-01-2001	Ludwig Inst. Cancer Res.		
	A3	WO 03/040299 A2	05-15-2003	Commissariat A L'Energie Atomique; Sedac Therapeutics		
	A4	WO 2005/026370 A2	03-24-2005	Aventis Pasteur Limited		
	A5	WO 2005/033278 A2	04-14-2005	Ludwig Inst. Cancer Res.		
	A6	WO 90/03184	04-05-1990	Morein, Bror et al.		
	A7	WO 99/53938	10-28-1999	Ludwig Inst. Cancer Res.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	Supplemental European Search Report for European (EPO) Application No. 04 78 9341 mailed on November 5, 2007, together with forms EPO Form 2901 and EPO PTO form 1507.4.	
	A9	BUSSON, Marc et al., "Prediction of CD4+ T Cell Epitopes Restricted to HLA-DP4 Molecules", <i>Journal of Immunological Method</i> , December 2006, vol. 317, no. 1-2, pp. 144-151- XP002428277.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 28, 2008 (use as many sheets as necessary)				Application Number	10/573,753
				Filing Date	September 30, 2004
				First Named Inventor	Jonathan CEBON
				Art Unit	1644
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	029860-0145

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
	A10	CHEN, Qiyuan et al., "Immunodominant CD4+ Responses Identified in a Patient Vaccinated with Full-Length NY-ESO-1 Formulated with ISCOMATRIX Adjuvant", <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 22 June 2004, vol. 101, no. 25, pp. 9363-9368, XP-002428274.			
	A11	JACKSON, Heather et al., "Striking Immunodominance Hierarchy of Naturally Occurring CD8+ and CD4+ T Cell Responses of Tumor Antigen NY-ESO-1", <i>Journal of Immunology</i> , 2006, May 2006, vol. 176, no. 10, pp. 5908-5917-XP002428276.			
	A12	MANDIC, Maja et al., "One NY-ESO-1-Derived Epitope that Promiscuously Binds to Multiple HLA-DR and HLA-DP4 Molecules and Stimulates Autologous CD4+ T Cells from Patients with NY-ESO-1-Expressing Melanoma", <i>Journal of Immunology</i> , February 2005, vol. 174, no. 3, pp. 1751-1759- XP002428278.			
	A13	VALMORI, Danla et la. "Epitope Clustering in Regions Undergoing Efficient Proteasomal Processing Defines Immunodominant CTL Regions of a Tumor Antigen", <i>Clinical Immunology</i> , vol. 122, no. 2, February 2007, pp. 163-172. XP-002428275.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.